Literature DB >> 32445940

DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.

Heidi L Casellas Román1, Kartika Venugopal2, Yang Feng2, Daniil E Shabashvili2, Luisa M Posada2, Jianping Li3, Olga A Guryanova4.   

Abstract

Entities:  

Keywords:  (DAC); AML; DNA hypomethylating agents (HMA); DNMT3A; Decitabine; MDS

Mesh：

Substances：

Year:  2020        PMID： 32445940      PMCID： PMC7481860          DOI： 10.1016/j.leukres.2020.106372

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  20 in total

1.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

2.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Authors:  Hsing-Chen Tsai; Huili Li; Leander Van Neste; Yi Cai; Carine Robert; Feyruz V Rassool; James J Shin; Kirsten M Harbom; Robert Beaty; Emmanouil Pappou; James Harris; Ray-Whay Chiu Yen; Nita Ahuja; Malcolm V Brock; Vered Stearns; David Feller-Kopman; Lonny B Yarmus; Yi-Chun Lin; Alana L Welm; Jean-Pierre Issa; Il Minn; William Matsui; Yoon-Young Jang; Saul J Sharkis; Stephen B Baylin; Cynthia A Zahnow
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 3.  DNMT3A in Leukemia.

Authors:  Lorenzo Brunetti; Michael C Gundry; Margaret A Goodell
Journal:  Cold Spring Harb Perspect Med       Date:  2017-02-01       Impact factor: 6.915

4.  Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

Authors:  S K Balasubramanian; M Aly; Y Nagata; T Bat; B P Przychodzen; C M Hirsch; V Adema; V Visconte; T Kuzmanovic; T Radivoyevitch; A Nazha; S Mukherjee; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2017-09-22       Impact factor: 11.528

Review 5.  Hypomethylating Agents as a Therapy for AML.

Authors:  Claude Gardin; Hervé Dombret
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

6.  DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Authors:  K H Metzeler; A Walker; S Geyer; R Garzon; R B Klisovic; C D Bloomfield; W Blum; G Marcucci
Journal:  Leukemia       Date:  2011-11-29       Impact factor: 11.528

7.  Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Authors:  F Traina; V Visconte; P Elson; A Tabarroki; A M Jankowska; E Hasrouni; Y Sugimoto; H Szpurka; H Makishima; C L O'Keefe; M A Sekeres; A S Advani; M Kalaycio; E A Copelan; Y Saunthararajah; S T Olalla Saad; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

8.  Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan.

Authors:  Suzanne Nguyen; Konstantinos Meletis; Dongdong Fu; Sonal Jhaveri; Rudolf Jaenisch
Journal:  Dev Dyn       Date:  2007-06       Impact factor: 3.780

9.  Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.

Authors:  M J Walter; L Ding; D Shen; J Shao; M Grillot; M McLellan; R Fulton; H Schmidt; J Kalicki-Veizer; M O'Laughlin; C Kandoth; J Baty; P Westervelt; J F DiPersio; E R Mardis; R K Wilson; T J Ley; T A Graubert
Journal:  Leukemia       Date:  2011-03-18       Impact factor: 11.528

10.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Authors:  Elsa Bernard; Yasuhito Nannya; Robert P Hasserjian; Sean M Devlin; Heinz Tuechler; Juan S Medina-Martinez; Tetsuichi Yoshizato; Yusuke Shiozawa; Ryunosuke Saiki; Luca Malcovati; Max F Levine; Juan E Arango; Yangyu Zhou; Francesc Solé; Catherine A Cargo; Detlef Haase; Maria Creignou; Ulrich Germing; Yanming Zhang; Gunes Gundem; Araxe Sarian; Arjan A van de Loosdrecht; Martin Jädersten; Magnus Tobiasson; Olivier Kosmider; Matilde Y Follo; Felicitas Thol; Ronald F Pinheiro; Valeria Santini; Ioannis Kotsianidis; Jacqueline Boultwood; Fabio P S Santos; Julie Schanz; Senji Kasahara; Takayuki Ishikawa; Hisashi Tsurumi; Akifumi Takaori-Kondo; Toru Kiguchi; Chantana Polprasert; John M Bennett; Virginia M Klimek; Michael R Savona; Monika Belickova; Christina Ganster; Laura Palomo; Guillermo Sanz; Lionel Ades; Matteo Giovanni Della Porta; Harold K Elias; Alexandra G Smith; Yesenia Werner; Minal Patel; Agnès Viale; Katelynd Vanness; Donna S Neuberg; Kristen E Stevenson; Kamal Menghrajani; Kelly L Bolton; Pierre Fenaux; Andrea Pellagatti; Uwe Platzbecker; Michael Heuser; Peter Valent; Shigeru Chiba; Yasushi Miyazaki; Carlo Finelli; Maria Teresa Voso; Lee-Yung Shih; Michaela Fontenay; Joop H Jansen; José Cervera; Yoshiko Atsuta; Norbert Gattermann; Benjamin L Ebert; Rafael Bejar; Peter L Greenberg; Mario Cazzola; Eva Hellström-Lindberg; Seishi Ogawa; Elli Papaemmanuil
Journal:  Nat Med       Date:  2020-08-03       Impact factor: 53.440
View more
  2 in total

Review 1.  Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.

Authors:  Daniil E Shabashvili; Yang Feng; Prabhjot Kaur; Kartika Venugopal; Olga A Guryanova
Journal:  Exp Hematol       Date:  2022-03-16       Impact factor: 3.249

Review 2.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.